Emerging role of IGF-1 in prostate cancer: A promising biomarker and therapeutic target
Changed side effect profile
A recent in vivo study in healthy subjects showed that acute intravenous infusion of GLP-1 during a pancreatic clamp, in which insulin and glucagon levels were maintained at basal levels, caused a reduction in hepatic glucose production, suggesting a potential direct effect on gluconeogenesis [11]
Its a triple-action medication that mimics the effects of three hormones: GLP-1, GIP, and glucagon
[1] [2] Renal and hepatic function may influence treatment outcomes
Microparticles can be formulated into diverse dosage forms such as dry powders, injectable suspensions (e.g., microspheres and liposomes), and are suitable for multiple routes of administration, including oral, pulmonary, and parenteral delivery, as summarized in Table 1B